Masimo Shareholders Approve \$180 per Share Acquisition by Danaher: Key Investor Insights

IRVINE, Calif. — May 4, 2026 — In a significant development for the medical technology sector, Masimo Corporation (Nasdaq: MASI), a leader in patient monitoring technologies, announced that its shareholders have overwhelmingly approved the proposed acquisition by Danaher Corporation (NYSE: DHR). The decision was made during a special virtual meeting of stockholders held on May 1, 2026.

Key Points from the Report

• Acquisition Approval: Masimo shareholders voted in favor of the Agreement and Plan of Merger, dated February 16, 2026, between Masimo, Danaher, and Mobius Merger Sub.
• Transaction Value: Under the terms of the merger, each share of Masimo common stock outstanding immediately prior to the effective time will be cancelled and automatically converted into the right to receive \$180.00 in cash, without interest.
• Corporate Structure Post-Merger: Following completion, Masimo will become an independent operating company within Danaher’s Diagnostics segment.
• Expected Closing: The merger is anticipated to close in 2026, pending the satisfaction of customary closing conditions, including regulatory approvals and clearances.

Important Considerations for Shareholders

• Compelling Value: The \$180 per share offer represents a cash payout for shareholders, which could be a premium over recent trading prices, depending on market performance leading up to the merger. This is a potentially price-sensitive event and could impact MASI’s share price as the transaction progresses.
• Regulatory and Closing Risks: The completion of the transaction is subject to several risks, including potential delays or failure to obtain necessary regulatory approvals, satisfaction of other closing conditions, or the possibility of the merger agreement being terminated under certain circumstances. Any of these risks could have a significant impact on Masimo’s share value and the likelihood/timing of shareholders receiving the merger consideration.
• Market Reaction: The announcement of the acquisition and its terms may cause volatility in Masimo’s stock price, especially if there are changes to the expected timeline, regulatory hurdles, or litigation related to the merger.
• Forward-Looking Statements and Risks: The company’s forward-looking statements caution investors about uncertainties including timing, completion, effects, and anticipated benefits of the merger. Shareholders should monitor developments closely, as unforeseen events could influence both Masimo and Danaher stock prices.

About Masimo

Masimo is recognized for its industry-leading monitoring solutions, including its flagship SET^® pulse oximetry technology, which is used in over 200 million patients worldwide each year and is the primary pulse oximetry technology at all of the top 10 U.S. hospitals as ranked by Newsweek’s 2025 World’s Best Hospitals listing. The company’s mission is to improve patient outcomes, reduce healthcare costs, and expand noninvasive monitoring to new applications and sites of care.

Risks and Cautionary Statements

• The merger is subject to various uncertainties, including timing, regulatory approvals, and the possibility that conditions to closing may not be satisfied.
• There is a risk of termination of the merger agreement, which could require Masimo to pay a termination fee.
• The announcement or pendency of the merger could impact Masimo and Danaher’s ability to retain or hire key personnel and maintain relationships with customers and suppliers.
• Stockholder litigation, costs of defense, and indemnification liabilities could result from the merger process.
• Restrictions during the pendency of the merger may limit Masimo and Danaher from pursuing other business opportunities.
• If the merger does not close, or is not perceived as beneficial, it could adversely affect Masimo’s share price.

Contact Information

Media: Longacre Square Partners ([email protected])
Investors: Eli Kammerman, Phone: (949) 297-7077, Email: [email protected]

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. The information is based on publicly available filings as of May 4, 2026. Investors are advised to review all official filings and consult their financial advisors before making any investment decisions. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.

View MASIMO CORP Historical chart here